The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 2060 -2063
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, P. T.
Right arrow Articles by Modlin, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, P. T.
Right arrow Articles by Modlin, R. L.

Cutting Edge: Vitamin D-Mediated Human Antimicrobial Activity against Mycobacterium tuberculosis Is Dependent on the Induction of Cathelicidin1

Philip T. Liu*, Steffen Stenger{dagger}, Dominic H. Tang* and Robert L. Modlin2,*

* Division of Dermatology, Department of Medicine, and Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and {dagger} Institute for Medical Microbiology and Hygiene, University of Ulm, Ulm, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
 References
 
Host defense against intracellular pathogens depends upon innate and adaptive antimicrobial effector pathways. TLR2/1-activation of monocytes leads to the vitamin D-dependent production of cathelicidin and, at the same time, an antimicrobial activity against intracellular Mycobacterium tuberculosis. To determine whether induction of cathelicidin was required for the vitamin D-triggered antimicrobial activity, the human monocytic cell line THP-1 was infected with M. tuberculosis H37Ra and then activated with the active vitamin D hormone 1,25-dihydroxyvitamin D3 (1,25D3). 1,25D3 stimulation resulted in antimicrobial activity against intracellular M. tuberculosis and expression of cathelicidin mRNA and protein. Using small interfering RNA (siRNA) specific for cathelicidin, 1,25D3-induced cathelicidin mRNA and protein expressions were efficiently knocked down, whereas a nonspecific siRNA control had little effect. Finally, 1,25D3-induced antimicrobial activity was completely inhibited in the presence of siRNA against cathelicidin, instead leading to enhanced intracellular growth of mycobacteria. These data demonstrate that cathelicidin is required for the 1,25D3-triggered antimicrobial activity against intracellular M. tuberculosis.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 Disclosures
 References
 
The innate immune response rapidly recognizes microbial pathogens, serving as a first line of defense against the infection by mounting an antimicrobial response. For the intracellular pathogen Mycobacterium tuberculosis, a role for vitamin D in the antimicrobial activity of human monocytes and macrophages was first suggested by in vitro experiments in the laboratories of Rook in 1986 (1) and Crowle in 1987 (2). These experiments were performed by infecting human monocytes and macrophages with M. tuberculosis followed by addition of the active vitamin D3 hormone 1,25-dihydroxyvitamin D3 (1,25D3).3 1,25D3 triggered significant antimicrobial activity, yet there was no information on the downstream mediators of the antimicrobial response.

Recently, we demonstrated that the activation of monocytes with a TLR2/1 ligand, the M. tuberculosis-derived 19-kDa lipopeptide, triggered a vitamin D-dependent pathway leading to induction of the antimicrobial peptide cathelicidin (3) and antimicrobial activity against intracellular M. tuberculosis (3, 4). The TLR antimicrobial pathway was dependent on the presence of 25-hydroxyvitamin D3 (25D3), which was converted in monocytes and macrophages by the CYP27b1-hydroxylase to 1,25D3. Addition of exogenous 1,25D3 to monocytes and PBMCs triggered an antimicrobial activity against intracellular M. tuberculosis (3, 5), similar to findings in the Rook and Crowle studies (1, 2). Furthermore, 1,25D3-stimulated monocytes and PBMCs expressed cathelicidin mRNA and protein (3, 5), confirming the findings of Wang et al. (6). In the present study, we sought to determine whether or not the vitamin D-triggered induction of cathelicidin was required for the vitamin D-induced antimicrobial activity against intracellular M. tuberculosis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 Disclosures
 References
 
Reagents and cells

THP-1 cells were purchased (American Type Culture Collection) and maintained in RPMI 1640 (Invitrogen Life Technologies) with 10% FCS (Omega Scientific). The M. tuberculosis H37Ra strain was a gift from Dr. J. Ernst (New York University School of Medicine, New York NY) and used as described below. 1,25D3 was purchased (BIOMOL International), stored at –80°C in amber tubes in small aliquots, and added to culture at concentrations of 10–7 M to 10–9 M for dose titration experiments or at 10–8 M, the concentration previously determined to be optimal for the provocation of THP-1 cells. [3H]Uracil was purchased (VWR International). The following Abs were purchased: {alpha}-cathelicidin (clone 1-1C12; Cell Sciences) and {alpha}-beta-actin (clone mAbcam 8226; Abcam). Predesigned small interfering RNA (siRNA) oligos were purchased (siGLO, siCTRL, and siCath; Dharmacon), resuspended, and stored as recommended by the manufacturer. Cell Line Nucleofector kit V was purchased and used for siRNA transfections (Amaxa).

Assay for bacterial viability

THP-1 cells were infected with M. tuberculosis H37Ra at an multiplicity of infection (MOI) of 1. The efficiency of infection was determined by auramine rhodamine stain and was regularly in the range of 30%, with an average of 1.2 bacteria per infected cell. Eighty-one percent of the infected cells contained one intracellular bacterium, 14% contained two bacteria, and 4% contained three or more. Infected cells were treated with 1,25D3 for 3 days in triplicate wells, pelleted by centrifugation, washed once with 1x PBS, and then lysed by resuspension in a 0.3% solution of saponin and vigorous pipetting. The lysate was centrifuged at 3300 x g for 20 min to pellet the harvested bacteria and then the supernatant was aspirated. Pellets were washed once with 1x PBS and resuspended in 7H9 broth and 3µCi of [3H]uracil and incubated for 24 h. The bacteria were then fixed at a final concentration of 2% paraformaldehyde for 20 min and harvested for liquid scintillation counting. Bacterial viability was calculated by dividing the average cpm values of the 1,25D3-treated wells by the average of the medium-treated wells. Intracellular bacteria were harvested and viability was also determined by CFU assay as described (3). To normalize for the variable starting material per experiment, the relative CFU were calculated by normalizing the values of the 1,25D3-treated cells to 105 CFU of the medium-treated cells.

Quantitative PCR (qPCR)

RNA was isolated using TRIzol reagent (Invitrogen Life Technologies), and cDNA was synthesized using the iSCRIPT cDNA synthesis kit (Bio-Rad). The sequences for 36B4 and Cyp24 were previously published and the methods described (3). The following primers were designed using Primer Express (Applied Biosystems): cathelicidin forward, 5'-GGACCCAGACACGCCAAA-3'; cathelicidin reverse, 5'-GCACACTGTCTCCTTCACTGTGA-3'. The relative quantities of the gene tested per sample were calculated against 36B4 using the delta delta threshold cycle ({Delta}{Delta}Ct) formula as previously described (7).

Intracellular flow cytometry

THP-1 cells were incubated for 18 h with 1,25D3 and their cathelicidin and beta-actin levels were assessed using intracellular flow cytometry as previously described (3, 8).

siRNA transfection

siRNA transfection into THP-1 cells was accomplished by using the Amaxa Nucleofector system and the Cell Line Nucleofector kit V according to the manufacturer’s recommendations with program U-001 for high viability. siRNA constructs were used at 100 pmol per transfection.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
Disclosures
 References
 
To ascertain the role of cathelicidin in 1,25D3-mediated antimicrobial activity against intracellular M. tuberculosis, we used siRNA technology to knock down cathelicidin gene transcripts. The human monocytic cell line THP-1 was selected because of its high efficiency of transfection with siRNAs and its subsequent viability after infection with M. tuberculosis. Furthermore, exposure of THP-1 cells to 1,25D3 is known to trigger an antimicrobial activity against intracellular M. tuberculosis (9). For the present initial studies, THP-1 cells were infected with the avirulent M. tuberculosis H37Ra at an MOI of 1 and then treated with 1,25D3 for 3 days. Subsequently, the intracellular bacteria were harvested and tested for bacterial metabolism according to [3H]uracil uptake or viability according to CFU. The addition of 1,25D3 to the infected THP-1 cells resulted in a 55% decrease in [3H]uracil uptake by the bacterium (p < 0.01; Fig. 1a) and a 28% decrease in total CFU harvested (p < 0.05; Fig. 1b), consistent with previous results (9).


Figure 1
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 1. 1,25D3 induces antimicrobial activity against intracellular M. tuberculosis H37Ra in THP-1 cells. THP-1 cells were infected with M. tuberculosis H37Ra for 18 h and treated with 10–8 M 1,25D3 for 3 days. Following treatment, the intracellular bacteria were harvested and then assayed for bacterial metabolism according to [3H]uracil uptake (a) and bacterial viability according to CFU (b). Data shown for [3H]uracil uptake represent the average bacterial viability percentage of four individual experiments (n = 4 ± SEM; **, p < 0.01). Bacterial viability was calculated as the 1,25D3 value divided by the medium-treated value multiplied by 100. CFU experiment is representative of three individual experiments (*, p < 0.05).

 
It should be noted that M tuberculosis H37Ra does not grow in THP-1 cells during the first 3 days of infection (data not shown) (10). The number of bacteria we observed after 3 days in the 1,25D3-treated cells was lower than the initial inoculums; therefore the activity of 1,25D3 is likely bactericidal rather than bacteriostatic. Although the percentage reduction of M. tuberculosis CFU was within an order of magnitude, M. tuberculosis infection in vivo can be produced by as few as 10–200 bacilli and is a slow process. In our experiments the time of in vitro assay was only 72 h, so a cumulative antimicrobial effect mediated by the vitamin D-cathelicidin innate immune pathway over time could have a profound effect on the number of bacilli during the course of infection.

Treatment of THP-1 cells with 1,25D3 up-regulated the cathelicidin mRNA expression in a dose-titratable manner from 48- to 140-fold induction (Fig. 2a). Cyp24 gene expression, a control vitamin D3 receptor downstream target gene, was similarly up-regulated, indicating that the vitamin D3 receptor was functional and activated (Fig. 2b). The up-regulation of the cathelicidin mRNA correlated with increased expression of the cathelicidin protein as detected by intracellular flow cytometry (Fig. 2c). These data indicate that the THP-1 cell line can be used for studying the relationship between 1,25D3-mediated antimicrobial activity and cathelicidin expression.


Figure 2
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 2. THP-1 cells express cathelicidin when incubated with 1,25D3. THP-1 cells were treated with 1,25D3 at concentration of 10–9 M, 10–8 M and 10–7 M for 18 h. a and b, Cathelicidin (Cath.) mRNA (a) and Cyp24 (b) mRNA levels were assayed using qPCR. Data shown are the average fold change (FC; value of 1,25D3-stimulated per value of medium-stimulated cells) of four experiments (n = 4 ± SEM). c, Protein levels of cathelicidin as measured by intracellular flow cytometry. Dotted line, solid line, and the gray shaded region indicate the isotype control, medium-treated cells, and 1,25D3-stimulated cells, respectively. Data shown are representative of four individual experiments.

 
A standard molecular approach for knocking down gene expression in human cells is the use of siRNAs. THP-1 cells were transfected with a nonspecific, fluorescently tagged siRNA construct and assessed for transfection efficiency and viability by flow cytometry and trypan blue exclusion, respectively. Following transfection, >99% of the cells were positive for intracellular siRNA and the cells were >99% viable (data not shown). Subsequently, THP-1 cells were transfected with either siRNAs specific for the cathelicidin gene (siCath) or a nonspecific control oligo (siCTRL) and then incubated with 1,25D3 or medium for 18 h. Transfection of siCath into THP-1 cells almost completely knocked down the 1,25D3-induced expression of cathelicidin mRNA, whereas siCTRL had little effect (Fig. 3a). The loss of cathelicidin mRNA expression also resulted in knockdown of cathelicidin at the protein level to that of the medium control as measured by intracellular flow cytometry (Fig. 3b). The knockdown was specific to cathelicidin, because neither siCath nor siCTRL affected 1,25D3-induced Cyp24 mRNA levels (Fig. 3c). The beta-actin levels did not change with either transfection or 1,25D3 treatment, indicating that reduction of the global protein levels was not the cause for the loss of cathelicidin expression (Fig. 3d). These results demonstrate that the 1,25D3-induced expression of cathelicidin can be efficiently knocked down in THP-1 cells while maintaining cell viability.


Figure 3
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 3. Knockdown of 1,25D3-induced cathelicidin via transfection of siRNA. a and b, siCath- and siCTRL-transfected as well as untransfected THP-1 cells were treated with 10–8 M 1,25D3 for 18 h and measured for cathelicidin mRNA expression by qPCR (a) and protein levels by intracellular flow cytometry (b). c and d, Cyp24 mRNA expression is measured by qPCR (c) and beta-actin levels are measured by intracellular flow cytometry (d). The dotted line, solid line, and the gray shaded region indicate the isotype control, medium-treated cells, and 1,25D3 stimulated cells, respectively, for the cytometry experiments. Data shown are from one representative experiment of four individual experiments.

 
To address the role of cathelicidin in 1,25D3-induced antimicrobial activity, siCath- and siCTRL-transfected as well as untransfected THP-1 cells were infected with H37Ra at an MOI of 1 for 18 h. The cells were then treated with medium alone or 1,25D3 for 3 days and the intracellular bacteria were harvested and assayed for viability by CFU and [3H]uracil uptake. Treatment with 1,25D3 reduced the viability of the intracellular bacteria by 30–50% in the untransfected and siCTRL transfected cells as measured by both [3H]uracil uptake (Fig. 4a) and CFU (Fig. 4b). The striking finding was that transfection with siCath completely blocked the 1,25D3-mediated antimicrobial activity, resulting in a 140 and 170% reduction of 1,25D3-induced antimicrobial activity according to [3H]uracil uptake (p < 0.05, siCath vs siCTRL; Fig. 4a) and CFU assay (p < 0.05, siCath vs siCTRL; Fig. 4b), respectively. These data suggest that cathelicidin is required for 1,25D3-mediated antimicrobial activity against intracellular M. tuberculosis in human monocytes.


Figure 4
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 4. The effects of cathelicidin knockdown on 1,25D3-mediated antimicrobial activity against intracellular M. tuberculosis. siCath- and siCTRL-transfected as well as untransfected THP-1 cells were infected with M. tuberculosis H37Ra at an MOI of 1 for 18 h and then treated with 10–8 M 1,25D3 for 3 days. Following treatment, the intracellular bacteria were harvested and assayed for bacterial metabolism according to [3H]uracil uptake (a) and bacterial viability according to CFU (b). Data shown for [3H]uracil uptake represent the average bacterial viability percentage of six individual experiments (n = 6 ± SEM; *, p < 0.05). Bacterial viability is calculated as the 1,25D3 value divided by the medium-treated value multiplied by 100. CFU data shown are the average of four individual experiments (n = 4 ± SEM). The data were normalized according to relative CFU proportionate to 105 CFU in the medium-treated samples.

 
Although it has been known for 20 years that exposure of human monocytes and macrophages to 1,25D3 results in antimicrobial activity against intracellular M. tuberculosis, the mechanism of this antimicrobial response has remained enigmatic. Potential mechanisms include activation of PI3K and the subsequent generation of reactive oxygen intermediates (9), NO (11, 12), and the tryptophan aspartate-containing coat protein TACO (13, 14). The present data advances our understanding of the role of vitamin D in innate immunity, indicating that the induction and expression of the antimicrobial peptide cathelicidin is required for the 1,25D3-mediated antimicrobial activity against intracellular avirulent M. tuberculosis in the human monocytic cell line THP-1. Nevertheless, additional experiments are needed to elucidate the role of cathelicidin as part of the TLR-mediated, vitamin D-dependent antimicrobial response against virulent M. tuberculosis in primary human monocytes and macrophages and the potential synergy of this pathway with other microbicidal effector pathways.

Progress in curtailing the human death rate from tuberculosis has been hampered by access to, the cost and effectiveness of current antibiotic regimens (15). Furthermore, the recent emergence of extensively drug resistant organisms is likely to have a global impact (16). Some of these problems could potentially be overcome by adding vitamin D to the treatment of tuberculosis, because a single oral dose increased the killing of mycobacteria in the blood of healthy donors (17), although the currently published studies on the effects of vitamin D supplementation are generally inadequate to evaluate the clinical efficacy of such treatment (18). Knowledge of the basic innate immune defense mechanisms against mycobacterial infection provides hope in the development of safe, simple, and cost-effective strategies to prevent and treat tuberculosis.


   Acknowledgments
 
We thank Drs. Stephan Krutzik and John Adams for scientific advice and Dominic Tang for technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by National Institutes of Health Grants R01 AI22553, R01 AI47868, and R01 AR40312. P.T.L. is supported by Microbial Pathogenesis Training Grant 2-T32-AI-07323. S.S. is funded by Deutsche Forschungsgemeinschaft SFB 643. Back

2 Address correspondence and reprint requests to Dr. Robert L. Modlin, Division of Dermatology, University of California Los Angeles, 52-121 Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail address: rmodlin{at}mednet.ucla.edu Back

3 Abbreviations used in this paper: 1,25D3, 1,25-dihydroxyvitamin D3; MOI, multiplicity of infection; qPCR, quantitative PCR; siRNA, small interfering RNA; siCath, siRNA specific for the cathelicidin gene; ciCTRL, nonspecific siRNA control oligo. Back

Received for publication May 16, 2007. Accepted for publication June 20, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
 References
 

  1. Rook, G. A. W., J. Steele, L. Fraher, S. Barker, R. Karmali, J. O’Riordan. 1986. Vitamin D3, {gamma} interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57: 159-163. [Medline]
  2. Crowle, A. J., E. J. Ross, M. H. May. 1987. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 55: 2945-2950. [Abstract/Free Full Text]
  3. Liu, P. T., S. Stenger, H. Li, L. Wenzel, B. H. Tan, S. R. Krutzik, M. T. Ochoa, J. Schauber, K. Wu, C. Meinken, et al 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773. [Abstract/Free Full Text]
  4. Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M. T. Ochoa, M. Engele, P. A. Sieling, P. F. Barnes, M. Rollinghoff, P. L. Bolcskei, M. Wagner, et al 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291: 1544-1547. [Abstract/Free Full Text]
  5. Martineau, A. R., K. A. Wilkinson, S. M. Newton, R. A. Floto, A. W. Norman, K. Skolimowska, R. N. Davidson, O. E. Sorensen, B. Kampmann, C. J. Griffiths, R. J. Wilkinson. 2007. IFN-{gamma}- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J. Immunol. 178: 7190-7198. [Abstract/Free Full Text]
  6. Wang, T. T., F. P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, J. Liao, L. Tavera-Mendoza, R. Lin, J. W. Hanrahan, S. Mader, J. H. White. 2004. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173: 2909-2912. [Abstract/Free Full Text]
  7. Monney, L., C. A. Sabatos, J. L. Gaglia, A. Ryu, H. Waldner, T. Chernova, S. Manning, E. A. Greenfield, A. J. Coyle, R. A. Sobel, et al 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541. [Medline]
  8. Garcia, V. E., P. A. Sieling, J. Gong, P. F. Barnes, K. Uyemura, Y. Tanaka, B. R. Bloom, C. T. Morita, R. L. Modlin. 1997. Single-cell cytokine analysis of {gamma} {delta} T cell responses to nonpeptide mycobacterial antigens. J. Immunol. 159: 1328-1335. [Abstract]
  9. Sly, L. M., M. Lopez, W. M. Nauseef, N. E. Reiner. 2001. 1{alpha},25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J. Biol. Chem. 276: 35482-35493. [Abstract/Free Full Text]
  10. Rajavelu, P., S. D. Das. 2007. A correlation between phagocytosis and apoptosis in THP-1 cells infected with prevalent strains of Mycobacterium tuberculosis. Microbiol. Immunol. 51: 201-210. [Medline]
  11. Weinberg, J. B., M. A. Misukonis, P. J. Shami, S. N. Mason, D. L. Sauls, W. A. Dittman, E. R. Wood, G. K. Smith, B. McDonald, K. E. Bachus, et al 1995. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86: 1184-1195. [Abstract/Free Full Text]
  12. Nozaki, Y., Y. Hasegawa, S. Ichiyama, I. Nakashima, K. Shimokata. 1997. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect. Immun. 65: 3644-3647. [Abstract]
  13. Anand, P. K., D. Kaul. 2005. Down-regulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microb. Lett. 250: 137-144. [Medline]
  14. Anand, P. K., D. Kaul. 2003. Vitamin D3-dependent pathway regulates TACO gene transcription. Biochem. Biophys. Res. Commun. 310: 876-877. [Medline]
  15. Zahrt, T. C., V. Deretic. 2001. Mycobacterium tuberculosis signal transduction system required for persistent infections. Proc. Natl. Acad. Sci. USA 98: 12706-12711. [Abstract/Free Full Text]
  16. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580. [Medline]
  17. Martineau, A. R., R. J. Wilkinson, K. A. Wilkinson, S. M. Newton, B. Kampmann, B. M. Hall, G. E. Packe, R. N. Davidson, S. M. Eldridge, Z. J. Maunsell, et al. 2007. A single dose of vitamin D enhances immunity to Mycobacteria. Am. J. Respir. Crit Care Med. In press.
  18. Martineau, A. R., F. U. Honecker, R. J. Wilkinson, C. J. Griffiths. 2007. Vitamin D in the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 103: 793-798. [Medline]



This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. Steinmann, S. Halldorsson, B. Agerberth, and G. H. Gudmundsson
Phenylbutyrate Induces Antimicrobial Peptide Expression
Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5127 - 5133.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
B. Rivas-Santiago, C. J. Serrano, and J. A. Enciso-Moreno
Susceptibility to Infectious Diseases Based on Antimicrobial Peptide Production
Infect. Immun., November 1, 2009; 77(11): 4690 - 4695.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. M. Bodnar, M. A. Krohn, and H. N. Simhan
Maternal Vitamin D Deficiency Is Associated with Bacterial Vaginosis in the First Trimester of Pregnancy
J. Nutr., June 1, 2009; 139(6): 1157 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. J. Wilkinson and C. Lange
Vitamin D and Tuberculosis: New Light on a Potent Biologic Therapy?
Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 740 - 742.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
J. S. Adams, S. Ren, P. T. Liu, R. F. Chun, V. Lagishetty, A. F. Gombart, N. Borregaard, R. L. Modlin, and M. Hewison
Vitamin D-Directed Rheostatic Regulation of Monocyte Antibacterial Responses
J. Immunol., April 1, 2009; 182(7): 4289 - 4295.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C.-S. Yang, D.-M. Shin, K.-H. Kim, Z.-W. Lee, C.-H. Lee, S. G. Park, Y. S. Bae, and E.-K. Jo
NADPH Oxidase 2 Interaction with TLR2 Is Required for Efficient Innate Immune Responses to Mycobacteria via Cathelicidin Expression
J. Immunol., March 15, 2009; 182(6): 3696 - 3705.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
N. Liu, A.T. Kaplan, J. Low, L. Nguyen, G.Y. Liu, O. Equils, and M. Hewison
Vitamin D Induces Innate Antibacterial Responses in Human Trophoblasts via an Intracrine Pathway
Biol Reprod, March 1, 2009; 80(3): 398 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. A. Ginde, J. M. Mansbach, and C. A. Camargo Jr
Association Between Serum 25-Hydroxyvitamin D Level and Upper Respiratory Tract Infection in the Third National Health and Nutrition Examination Survey
Arch Intern Med, February 23, 2009; 169(4): 384 - 390.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Krutzik, M. Hewison, P. T. Liu, J. A. Robles, S. Stenger, J. S. Adams, and R. L. Modlin
IL-15 Links TLR2/1-Induced Macrophage Differentiation to the Vitamin D-Dependent Antimicrobial Pathway
J. Immunol., November 15, 2008; 181(10): 7115 - 7120.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
W. B. Grant
To the Editors
Eur. Respir. J., November 1, 2008; 32(5): 1412 - 1413.
[Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. H. White
Vitamin D Signaling, Infectious Diseases, and Regulation of Innate Immunity
Infect. Immun., September 1, 2008; 76(9): 3837 - 3843.
[Full Text] [PDF]

Home page
 J EndocrinolHome page
R. F Chun, J. S Adams, and M. Hewison
Back to the future: a new look at 'old' vitamin D
J. Endocrinol., August 1, 2008; 198(2): 261 - 269.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Moeenrezakhanlou, L. Shephard, L. Lam, and N. E. Reiner
Myeloid cell differentiation in response to calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein downstream of phosphatidylinositol 3-kinase
J. Leukoc. Biol., August 1, 2008; 84(2): 519 - 528.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Bastian, T. Braun, H. Bruns, M. Rollinghoff, and S. Stenger
Mycobacterial Lipopeptides Elicit CD4+ CTLs in Mycobacterium tuberculosis-Infected Humans
J. Immunol., March 1, 2008; 180(5): 3436 - 3446.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, P. T.
Right arrow Articles by Modlin, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, P. T.
Right arrow Articles by Modlin, R. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS